Serum ferroxidase activity in patients with multiple sclerosis: A pilot study

In Vivo

Volumn 28, Issue 6, 2014, Pages 1197-1200

  Cervellati, Carlo ^a   Romani, Arianna ^a   Fainardi, Enrico ^b   Trentini, Alessandro ^a   Squerzanti, Monica ^a   Baldi, Eleonora ^b   Caniatti, Maria Luisa ^b   Granieri, Enrico ^a   Bellini, Tiziana ^a   Castellazzi, Massimiliano ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Ceruloplasmin; Ferroxidase activity; Multiple sclerosis; Oxidative stress

Indexed keywords

CERULOPLASMIN;

ADULT; ARTICLE; CERULOPLASMIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PILOT STUDY; BLOOD; ENZYME ACTIVATION; METABOLISM; MIDDLE AGED;

ADULT; CERULOPLASMIN; ENZYME ACTIVATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PILOT PROJECTS;

EID: 84918555389     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Goverman J: Autoimmune T-cell responses in the central nervous system. Nat Rev Immunol 9: 393-407, 2009.
2. Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Harris ZL, Klomp LW and Gitlin JD: Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 67(Suppl): 972S-977S, 1998.
3. van Horssen J, Witte ME, Schreibelt, G and De Vries, HE: Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 1812(2): 141-150, 2011.
4. Bergamini CM, Gambetti S, Dondi A and Cervellati C: Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 10(4): 1611-1626, 2004.
5. Qian ZM and Ke Y: Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res Rev 35(3): 287-294, 2011.
6. Erel O: Automated measurement of serum ferroxidase activity. Clin Chem 44(11): 2313-2319, 1998.
7. Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, Bush AI and Finkelstein DI: Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 73 (4): 554-559, 2013.
8. Harris ZL, Klomp LW and Gitlin JD: Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 67(Suppl): 972S-977S, 1998.
9. Khalil M, Teunissen C and Langkammer C: Iron and neurodegeneration in multiple sclerosis. Mult Scler Int 2011: 606807, 2011.
10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B and Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol 69: 292-302, 2011.
11. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11): 1444-1552, 1983.
12. Boll MC, Alcaraz-Zubeldia M, Montes S and Rios C: Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NOx content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33(9): 1717-1723, 2008.
13. Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, Barbariga M, Codazzi F, Pelizzoni I, Magnani G, Pesca M, Franciotta D, Cappa SF and Alessio M: Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 31(50): 18568-18577, 2011.
14. McNeill A, Pandolfo M, Kuhn J, Shang H and Miyajima H: The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 60(4): 200-205, 2008.
15. de Bie P, Muller P, Wijmenga C and Klomp LW: Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet 44(11): 673-688, 2007.